

# ForPatients

*by Roche*

Huntington Disease (HD)

## An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of RO7234292 (RG6042) in Patients With Huntington's Disease

**Trial Status**  
Completed

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT03842969 2018-003898-94  
BN40955

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03842969 2018-003898-94 BN40955**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥25 Years

**Healthy Volunteers**  
No

---